However, also in patients receiving various types of adjuvant endocrine and/or chemotherapy, the analysis came out as significant, suggesting that overall, the APOBEC3B enzyme contributes to breast cancer progression. This evidence concerns the gene APOBEC3B and breast carcinoma.